85results about How to "Reduced expression level" patented technology

The invention discloses a Lactobacillus paracasei metagen with a constipation relieving effect and application thereof, and belongs to the field of microorganisms. The lactobacillus paracasei CCFM1452 provided by the invention is relatively good in activity, and has certain acid and alkali resistance and adhesion. According to the present invention, with the application of the lactobacillus paracasei CCFM1452, the inflammation level in the colon tissue can be significantly reduced, the pathological damage of the colon tissue can be improved, the levels of the proinflammatory factor and the anti-inflammatory factor can be adjusted, the aquaporin expression level can be reduced, and the motilin MTL content in the colon tissue can be increased; the content of vasoactive intestinal peptide VIP in the colon tissue is reduced; the compound has the advantages of enhancing intestinal tract movement, shortening intestinal tract transfer time and regulating intestinal tract steady state, and has a huge application prospect in preparation of medicines for relieving constipation.

The invention relates to application of VBIT-4 or pharmaceutically acceptable salt thereof in preparation of drugs for preventing or treating vitiligo and complications thereof. A large number of modern pharmacological scientific researches and in-vivo pharmacodynamic tests prove that VBIT-4 has a treatment effect on a leucoderma mouse model and inhibits synthesis of inflammatory factors and chemotactic factors in a leucoderma mouse skin lesion area. The mechanism of the invention is that VBIT-4 inhibits the expression of inflammatory factors and chemotactic factors in skin tissues so as to treat leucoderma, compared with the existing treatment means, VBIT-4 can promote the compound color of pigments in a skin lesion region on the back of a leucoderma mouse, has no obvious toxicity, and reduces the expression level of inflammatory factors (IL-1beta, IL-6 and IFN-alpha) and chemotactic factors (CXCL9 and CXCL10). In conclusion, the VBIT-4 is clear in action mechanism, remarkable in effect and free of obvious side effects, and has remarkable advantages and progress compared with existing drugs.

The invention discloses small protein UFD1s and application of the small protein UFD1s in prevention, treatment and diagnosis of non-alcoholic steatohepatitis, the small protein UFD1s provided by the invention has the effects of regulating energy metabolism and resisting cell stress, and the UFD1s can be used as an auxiliary diagnosis marker of the non-alcoholic steatohepatitis (NASH). Meanwhile, the deletion or low expression quantity of the UFD1s is related to the occurrence and development of the NASH, the UFD1s are expressed in vivo through the constructed expression substance and method, the effect of preventing and / or treating the NASH can be played, and a new thought is provided for preventing and / or treating the NASH.

The invention discloses combined lactobacillus salivarius CCFM1398 for regulating and controlling bone homeostasis and relieving bone resorption and a metagen of the combined lactobacillus salivarius CCFM1398, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius CCFM1398 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that expression of protein level and gene level of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors TNF-alpha, IL-6 and MPO of the orthodontic bone absorption rat is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention discloses a combined lactobacillus salivarius CCFM1397 for improving osteoblast activity and relieving bone resorption and periodontal tissue damage and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus salivarius combination CCFM1397 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that: the expression of MC3T3-E1 cell osteoprotegerin (OPG) protein and gene level is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors IL-1beta, IL-6 and TNF-alpha and myeloperoxidase MPO of the orthodontic bone absorption rats is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention belongs to the technical field of drug co-delivery, and particularly relates to a nano-platform based on attenuated bacterial outer membrane vesicles and capable of achieving co-delivery of siRNA and adriamycin and a preparation method of the nano-platform. The preparation method comprises the following steps: synthesizing an ROS response type cationic polymer PTP; the preparation method comprises the following steps: preparing aptamer-DOX; preparing an ROS (reactive oxygen species) response type positive electric nano core PTP / 47aD; extracting and purifying the [delta] msbB OMVs; synthesizing a target functional unit DSPE-PEG2k-Angiopep-2 (Distearoyl Phosphate Polyethylene Glycol 2k-Angiopep-2); finally, the ROS response type co-delivery nano platform AO (at) PTP / 47aD is prepared and obtained. The co-delivery nano-platform prepared by the invention is relatively small in particle size, uniform in morphology and relatively high in biological safety, and has no obvious damage to various tissues and visceral organs. The glioblastoma immunopotentiator can be used as a general platform for gene delivery, can also be used as an immune activator, is suitable for intravenous injection administration, and can comprehensively overcome immune resistance of glioblastoma.

The invention relates to the technical field of biomedicine. The invention provides a phosphorylated protein marker for angiogenesis of glioma and application of the phosphorylated protein marker. Through a series of analysis such as iTRAQ quantitative phosphorylated proteomics, KEGG signal channel enrichment, a kinase spectrum, glioblastoma transcriptome high-throughput sequencing data and immunohistochemistry, it is determined that significantly different phosphorylated proteins and related signal channels can significantly affect neuroglioma angiogenesis; and the phosphorylated protein changes along with tumor progression, and is a phosphorylated protein marker and a potential therapeutic target for glioma angiogenesis.

The invention discloses application of an epidermal protein gene SlituCP26 in prevention and treatment of prodenia litura, and relates to the technical field of biology. The nucleotide sequence of the SlituCP26 gene is shown as SEQ ID NO: 1, the SlituCP26 gene is highly expressed in an indoxacarb resistant strain, dsRNA of the gene is prepared, the dsRNA is micro-injected into prodenia litura larvae, after injection, the expression level of the SlituCP26 gene is obviously reduced, the body type of the larvae is obviously reduced, the epidermis thickness is obviously reduced, and the sensitivity to indoxacarb is obviously improved. The invention also provides a SlituCP26 gene promoter, and the drug resistance of the prodenia litura can be detected through the difference in sequence after the promoter is amplified. According to the invention, the fact that the epidermal protein SlituCP26 gene participates in the effect of the prodenia litura on resisting insecticides and the formation process of a resistance mechanism is clear, and the epidermal protein SlituCP26 gene has theoretical significance on the development of new insecticides.

The invention discloses a virus-induced gene silencing technology in hydrangea macrophylla, and belongs to the technical field of hydrangea macrophylla gene function research. Comprising the following steps: (1) cloning full-length fragments of HmPDS, HmF3 '5' H and HmCHS1 genes; (2) respectively constructing TRV vectors of HmPDS, HmF3 '5' H and HmCHS1, and transforming escherichia coli and agrobacterium; (3) infecting the hydrangea macrophylla material with agrobacterium; and (4) culturing the hydrangea macrophylla after infection. The invention provides a virus-induced gene silencing technology in hydrangea macrophylla, which is characterized in that a hydrangea macrophylla cultivated species' Ampelopsis' is used as a material to respectively infect tissue culture seedlings and flower heads. According to the gene instantaneous silencing method disclosed by the invention, related genes in the hydrangea can be effectively silenced, and the gene function research efficiency can be improved.

The invention belongs to the field of biological medicine, and particularly relates to application of forsythiaside A in preparation of a medicine for relieving or treating diabetic cardiomyopathy. The forsythiaside A relieves or treats diabetic cardiomyopathy by regulating NLRP3 activation induced by endoplasmic reticulum stress. The forsythiaside A can reduce the levels of BG, GSP, TG, LDH, CK-MB, cTnI, MDA, IL-1beta, IL-6 and TNF-alpha of STZ induced diabetic mice, and meanwhile, the levels of IN and SOD are increased. The forsythiaside A can be used for reducing the expression levels of IL-1beta, IL-6, TNF-alpha, GRP78, TXNIP and NLRP3 in H9c2 cells induced by Glu. Therefore, forsythiaside A can induce NLRP3 inflammasome activation through endoplasmic reticulum stress to relieve diabetic cardiomyopathy, and a theoretical basis is provided for treating diabetic cardiomyopathy.

The invention provides a traditional Chinese medicine preparation for dispelling wind and eliminating dampness and application, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of honeysuckle stem, spatholobus stem, silkworm excrement, gentian, safflower, peach kernel, ash bark, arisaema cum bile, medicated leaven and honeycomb; the traditional Chinese medicine preparation can remarkably reduce the ankle joint swelling degree of an acute gouty arthritis model rat, reduce the expression level of inflammatory factors such as TNF-alpha, IL-1beta and IL-6 in serum and reduce the content of uric acid, creatinine and XOD in the serum, so that the effects of resisting inflammation, easing pain and reducing blood uric acid are achieved; clinical test results show that the traditional Chinese medicine preparation can relieve the pain degree of a patient, reduce the levels of inflammation-related factors TNF-alpha and IL-1beta in knee joint synovial fluid of the patient, reduce inflammation indexes WBC, ESR and CRP in serum, relieve the inflammatory reaction of the body of the patient, reduce the occurrence rate of adverse reactions, and improve the curative effect of the patient. A novel traditional Chinese medicine preparation with high safety and good curative effect is provided for treatment of acute gout.

The invention discloses a substance with anti-allergic activity and application thereof, the substance with anti-allergic activity is a bitter receptor stimulant, and the bitter receptor stimulant is selected from at least one of denatonium benzoate, difenidol and quinine. The compound can reduce the expression level of IgE in serum, inhibit mast cell degranulation and regulate and control expression of cytokines at the downstream of Th1, Th2 and Dc cells, so that allergy is prevented and allergic symptoms are relieved, and the compound can be used for preparing medicines, health foods, functional foods and dietary supplements for preventing and relieving food allergy.

The invention discloses a mini-chromosome state characterization cell model for drug screening. The mini-chromosome state characterization cell model is a transfected cell obtained by co-transfecting a hepatocyte line with prcccDNA-HiBiT-HBx and a plasmid Cre; the invention also discloses an application of the compound C20H14F3N3S or the pharmaceutically acceptable salt thereof in preparation of an HBV (hepatitis B virus) inhibitor or a medicine for treating hepatitis B virus infectious diseases or symptoms. According to the invention, a novel anti-hepatitis B virus small molecule compound is screened by utilizing a constructed cell model, and experiments prove that the novel anti-hepatitis B virus small molecule compound can obviously reduce the expression levels of HBV total RNAs, HBeAg, HBV pgRNA and HBV nucleoprotein.

The present invention relates to the use of extracellular vesicle-like nanoparticles derived from Atractylodes macrocephala in the preparation of drugs for preventing or treating intestinal diseases. The present invention creatively extracts and purifies extracellular vesicles derived from the traditional Chinese medicine Atractylodes macrocephala, and studies its physiological effects, and finds that it can be fully internalized and absorbed by macrophages, can reduce the expression level of inflammatory factors in macrophages, and has in vivo intestinal targeting. Animal experiments have proved that it can reduce the disease activity index of ulcerative colitis mouse models, alleviate the destruction and atrophy of crypt glands in colon tissue, and reduce the expression level of inflammatory factors in mouse colon tissue. It has the potential to be used in the preparation of drugs for preventing or treating intestinal diseases, and provides a new strategy for preventing or treating intestinal diseases, especially enteritis, ulcerative enteritis, and ulcerative colitis.

The invention discloses a method for constructing a VIGS silencing system of a Zizania latifolia ZlPDS gene and a product thereof, by constructing a foxtail mosaic virus (FoMV)-mediated gene silencing expression vector pFoMV-PDS plasmid containing a Zizania latifolia ZlPDS gene-specific fragment, and transforming Zizania latifolia by Agrobacterium-mediated method, inducing the silencing of a target gene ZlPDS, effectively reducing the expression level of the ZlPDS gene, being able to diffuse and propagate for a long time in Zizania latifolia plants, and causing the leaf to become white. The invention establishes a Zizania latifolia ZlPDS gene VIGS silencing system with high silencing efficiency in Zizania latifolia, which can be used to verify the function of the target gene, overcomes the difficulty of Zizania latifolia genetic transformation, simplifies the operation steps, and lays a foundation for studying the gene function of Zizania latifolia.

The invention discloses a hematological marker and a kit for colorectal cancer diagnosis, and belongs to the technical field of colorectal cancer detection. The hematological marker is a serum exosome tsRNA-Glu-i-0315, and the sequence of the serum exosome tsRNA-Glu-i-0315 is as shown in SEQ ID NO. 1 (sequence identifier number 1). The kit for early diagnosis or progress early warning of colorectal cancer comprises a fluorescent PCR reaction system, the fluorescent PCR reaction system comprises a forward primer aiming at the tsRNA-Glu-i-0315 and a reverse primer aiming at the tsRNA-Glu-i-0315, and the forward primer and the reverse primer are used for detecting the tsRNA-Glu-i-0315. 1, and the sequence of a forward primer aiming at the tsRNA-Glu-i-0315 is as shown in SEQ ID NO. 2. By detecting tsRNA-Glu-i-0315, it is proposed for the first time that compared with healthy volunteers, the expression level of tsRNA-Glu-i-0315 in serum exosomes of colorectal cancer patients is remarkably reduced, ROC curve analysis shows that AUC is 0.789, the sensitivity is 86.8%, and the specificity is 62.5%.

The invention discloses application of triflorin or pharmaceutically acceptable salt or solvate thereof in preparation of a medicine for preventing, delaying and / or treating heart aging and / or myocardial injury. The invention provides a new strategy and a candidate substance for developing medicines, health-care products or functional foods for preventing, delaying and / or treating heart aging and / or myocardial injury, maintaining heart health and reducing the risk of aging-related cardiovascular diseases.

The invention discloses application of dauricine in preparation of a medicine for treating non-small cell lung cancer, belongs to medical application of the dauricine in the technical field of biological medicines, and creatively discovers that the dauricine has an excellent effect of treating the non-small cell lung cancer. The proliferation of non-small cell lung cancer cells can be inhibited by reducing mitochondrial membrane potential, inhibiting Notch3 protein activity, reducing the expression level of DLL4 protein and the like; meanwhile, a good treatment effect is shown in a non-small cell lung cancer mouse model, growth and proliferation of non-small cell lung cancer cells can be remarkably inhibited, apoptosis of the non-small cell lung cancer cells is induced, depolarization of mitochondria of the non-small cell lung cancer cells is induced, Notch3 protein activity is remarkably inhibited, expression of DLL4 protein is reduced, and the anti-cancer effect is achieved. The invention provides a new path for the application of the dauricine in treating the non-small cell lung cancer, and provides a new thought and strategy for the development and utilization of the dauricine.

The present disclosure relates to a novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP2, MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.

The invention relates to the technical field of recombinant protein expression and cell culture. The invention provides an application of an ANXA1 gene as a recombinant protein expression regulation target, a nucleic acid fragment and a plasmid for regulating the gene, and a prepared CHO cell line. By silencing / inhibiting ANXA1 gene expression of CHO cells, the cell proliferation capacity is regulated and controlled, and the yield of recombinant protein is increased; the method specifically comprises the following steps: inserting and integrating an shRNA fragment of a targeted ANXA1 gene into a piggyBac transposon vector, and constructing an shRNA transposon vector; the shRNA transposon carrier is continuously and efficiently catalyzed by PBase to be integrated into the genome of the CHO cell, so that the continuous interference effect of the gene in the CHO cell is realized. The CHO cell line constructed by the invention can significantly reduce the mRNA and protein expression level of ANXA1, and as a host cell for recombinant protein expression, the CHO cell line multiplies the expression quantity of recombinant protein.

An object of the present invention is to provide a manufacturing method of an adeno-associated virus, which can improve a production amount of the adeno-associated virus, and to provide a cell and an expression vector for use in the manufacturing method of an adeno-associated virus. According to the present invention, provided is a manufacturing method of an adeno-associated virus, including expressing an E4ORF6 gene with an exogenous promoter, in which expression of E4ORF6 is reduced as compared with a case where E4ORF6 is expressed using an expression unit containing an enhancer, a cytomegalovirus-derived promoter, a Kozak sequence, an E4ORF6 gene, and a polyA signal sequence.

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.

The invention belongs to the technical field of medicines, and particularly provides a novel application of methyl cedryl ether in preparation of a product for resisting skin photoaging. Cell experiment evaluation proves that the methyl cedryl ether has no obvious influence on the activity of dermal Hs68 fibroblasts at the concentration of 12.5-100 mu M, and meanwhile, the methyl cedryl ether can obviously increase the content of hyaluronic acid in light-aged Hs68 cells induced by medium-wave ultraviolet rays (UVB), improve the mRNA expression level of COL1A2 and COL3A1, improve the mRNA expression level of HAS1 and HAS3 and reduce the mRNA expression level of MMP-1, MMP-3 and MMP-9. Therefore, the methyl cedryl ether provided by the invention can be applied to preparation of products for resisting skin photoaging.

The invention relates to the technical field of biological medicine, and discloses a binding peptide targeting a C-terminal structural domain of human AARS1 protein and application, the binding peptide comprises an amino acid sequence represented by a general formula (I) and a Val-Ala-Xaa-Xaa-Arg-His core motif, and can specifically bind to the C-terminal structural domain of the human AARS1 protein. The binding peptide and the derivative thereof block an AARS1 mediated protein lactic acid modification signal channel by inhibiting the activity of AARS1 lactoacyltransferase or inducing protein degradation through a ubiquitin-proteasome pathway. The binding peptide provided by the invention avoids an N-terminal catalytic activity center of AARS1, does not influence the protein synthesis function of normal cells while exerting antitumor activity, has relatively high affinity and safety, and can be used for preparing drugs for treating AARS1 mediated diseases such as pancreatic cancer or a diagnostic reagent for detecting AARS1.

The invention relates to application of sulfated glycogen synthase kinase-3 in prevention and treatment of liver insulin resistance. Specifically, the invention provides an application of a hyposulfated GSK-3beta inhibitor in preparation of a medicine, and the medicine is used for preventing or treating insulin resistance; the invention further discloses application of the GSK-3beta knockout reagent in preparation of a medicine. The medicine is used for preventing or treating insulin resistance.

The present invention relates to the field of microorganisms, and specifically to providing a new functional lactic acid bacteria expressing ETEC antigens, and a preparation method and application thereof. The recombinant Lactobacillus plantarum expressing ETEC antigens uses Lactobacillus plantarum NC8 as a host bacterium and a pPG612.1 expression vector, wherein the pPG612.1 expression vector contains the FaeC gene or LngC gene of ETEC. The present invention innovatively integrates the FaeC and LngC genes of ETEC into Lactobacillus plantarum NC8 for expression, and can activate the intestinal mucosal immune response by oral administration, which can not only directly counteract the intestinal damage caused by ETEC and protect the intestinal villus structure, but also can regulate the intestinal microenvironment, stimulate the body to produce a systemic immune response, improve the body's ability to resist ETEC infection, reduce the morbidity and mortality of ETEC infection, and thus improve the economic benefits of the pig farming industry.

The invention relates to eye drops for treating xerophthalmia and a preparation method of the eye drops. The eye drops are prepared from the following components in percentage by mass: 0.05 to 0.5 percent of a wild mint extract, 0.1 to 0.4 percent of lutein-coated sericin nano-particles, 0.1 to 0.5 percent of chondroitin sulfate, 0.9 to 1.0 percent of sodium chloride, 0.05 to 0.1 percent of poloxamer, 0.01 to 0.1 percent of EDTA (Ethylene Diamine Tetraacetic Acid), a phosphate buffer solution and water. The particle size of the lutein-coated sericin nanoparticles is 50-300nm, the water is medicinal sterile water, and the pH value of the eye drops is adjusted to 7.0-7.8 by the phosphate buffer solution. The eye drops can effectively relieve dry eye symptoms, provide long-time wetting and protection, reduce eye inflammation and oxidative stress, promote repair of corneal injury and effectively reduce the expression level of inflammatory factors, and are high in use safety.

The invention belongs to the field of biological medicine, and particularly relates to novel application of an RTKs / RAS / RAF / c-Myc signal channel inhibitor. The invention discloses application of an RTKs / RAS / RAF / c-Myc signal channel inhibitor as a ferroptosis inhibitor. The RTKs signal channel inhibitor comprises BMS-599626, Lapatinib, and Ripretinib, and is characterized in that the RTKs signal channel inhibitor comprises BMS-599626, Lapatinib, and Ripretinib. And the RAS / RAF signal channel inhibitor comprises Lonafarnib and AZ628 (Azosulfuron 628). The c-Myc signal channel inhibitor comprises 10074-G5 and 10058-F4, and the c-Myc signal channel inhibitor comprises 10074-G5 and 10058 The invention provides a new thought for application of the RTKs / RAS / RAF / c-Myc signal channel inhibitor as a novel ferroptosis inhibitor in treatment of injury-related diseases.

The invention discloses application of a killer cell lectin-like receptor C3 (KLRC3) gene as a marker in preparation of a detection preparation for systemic lupus erythematosus (SLE) secondary hemophagic lymphocytosis (HLH). The preparation is used for detecting the expression level of the KLRC3 gene in a biological sample. Researches find that the expression level of the KLRC3 gene in an SLE secondary HLH patient is obviously lower than that of a healthy control group and an SLE patient, and the KLRC3 gene has good diagnosis sensitivity and specificity. The invention further discloses a preparation for detecting the expression level of the KLRC3 gene in a biological sample of a patient, the preparation contains a primer pair for detecting the mRNA level expressed by the KLRC3 gene or an antibody for detecting the protein level expressed by the KLRC3 gene, whether the SLE patient has secondary HLH or not can be detected only by drawing blood and extracting peripheral blood mononuclear cells (PBMC), the operation is simple and rapid, and the result is accurate.

The invention relates to application of capillary artemisia derived extracellular vesicle-like nanoparticles in preparation of medicines for preventing or treating liver diseases, and creatively extracts and purifies traditional Chinese medicine capillary artemisia derived extracellular vesicles, researches the physiological efficacy of the extracellular vesicles, and finds that the extracellular vesicles can be fully internalized and absorbed by normal liver cells of people, and can be used for treating liver diseases. Animal experiments prove that the traditional Chinese medicine composition has good effects of dispelling the effects of alcohol and protecting the liver, effectively improves liver injury, reduces the expression level of inflammatory factors, has a protection effect on mitochondria in liver tissues, and can be applied to preparation of the medicines for dispelling the effects of alcohol and protecting the liver.